To the best of our knowledge, there are no mutational data, such as high-copy gene amplification, gene fusions and translocations, or recurrent localized missense mutations that establish clear-cut gain-of-function defects for SOX9 in CRCs, which are the types of genetic data needed to support a role for SOX9 as an oncogene in CRC biology, akin to the genetic evidence that exists for known oncogenes, such as MYC, KRAS, and BRAF. The gene discussed is BRAF; the disease is colorectal carcinoma.